Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04015102 · ClinicalTrials.gov registry record
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Completed
- Registry status
- 255
- Enrollment target
NCT04015102: Completed study, sponsored by Myriad Genetic Laboratories.
NCT04015102 is a clinical trial that has completed, run by Myriad Genetic Laboratories. The registered enrollment target is 255 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04015102 has completed, sponsored by Myriad Genetic Laboratories.
- COMPLETED
- Registry status
- 255 participants
- Enrollment target
Study Summary
This prospective registry will evaluate the feasibility and impact of implementing standard cancer family history review and guideline-aligned genetic testing for men diagnosed with Prostate Cancer in community urology practices nationwide.
Primary Outcome
To see how practical it would be to integrate a standard hereditary cancer risk assessment , patient counseling and genetic testing process into the community urology practice setting. Also to evaluate the impact of the integrated process on provider and patient satisfaction. This registry will gather information to evaluate the feasibility of HCRA and genetic testing process integration in the Urology community practice setting. Analysis of the registry will compare historical pre-process integ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2020-10-30 |
What the finished NCT04015102 record still lists
NCT04015102 is an observational study that tracks outcomes without assigning an intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04015102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04015102 about?
NCT04015102 is a clinical study titled "A Registry for Hereditary Cancer Risk Assessment and Genetic Testing". This prospective registry will evaluate the feasibility and impact of implementing standard cancer family history review and guideline-aligned genetic testing for men diagnosed with Prostate Cancer in community urology practices nationwide.
What is the current status of trial NCT04015102?
This trial is currently completed. The enrollment target is 255 participants. The study started on 2019-03-06. Estimated completion is 2020-10-30.
Who is sponsoring clinical trial NCT04015102?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI